It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment
Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organi...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Stewart, Rebecca E. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021transfer abstract |
|---|
| Übergeordnetes Werk: |
Enthalten in: Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment - 2013, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:120 ; year:2021 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jsat.2020.108176 |
|---|
| Katalog-ID: |
ELV052332691 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV052332691 | ||
| 003 | DE-627 | ||
| 005 | 20230626033125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jsat.2020.108176 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001226.pica |
| 035 | |a (DE-627)ELV052332691 | ||
| 035 | |a (ELSEVIER)S0740-5472(20)30433-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Stewart, Rebecca E. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment |
| 264 | 1 | |c 2021transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. | ||
| 520 | |a Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. | ||
| 700 | 1 | |a Wolk, Courtney Benjamin |4 oth | |
| 700 | 1 | |a Neimark, Geoffrey |4 oth | |
| 700 | 1 | |a Vyas, Ridhi |4 oth | |
| 700 | 1 | |a Young, Jordyn |4 oth | |
| 700 | 1 | |a Tjoa, Chris |4 oth | |
| 700 | 1 | |a Kampman, Kyle |4 oth | |
| 700 | 1 | |a Jones, David T. |4 oth | |
| 700 | 1 | |a Mandell, David S. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment |d 2013 |g Amsterdam [u.a.] |w (DE-627)ELV011527242 |
| 773 | 1 | 8 | |g volume:120 |g year:2021 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jsat.2020.108176 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_30 | ||
| 912 | |a GBV_ILN_40 | ||
| 936 | b | k | |a 44.40 |j Pharmazie |j Pharmazeutika |q VZ |
| 951 | |a AR | ||
| 952 | |d 120 |j 2021 |h 0 | ||
| author_variant |
r e s re res |
|---|---|
| matchkey_str |
stewartrebeccaewolkcourtneybenjaminneima:2021----:tntuthmnyhrlotetetdooynulcyuddusa |
| hierarchy_sort_str |
2021transfer abstract |
| bklnumber |
44.40 |
| publishDate |
2021 |
| allfields |
10.1016/j.jsat.2020.108176 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001226.pica (DE-627)ELV052332691 (ELSEVIER)S0740-5472(20)30433-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.40 bkl Stewart, Rebecca E. verfasserin aut It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. Wolk, Courtney Benjamin oth Neimark, Geoffrey oth Vyas, Ridhi oth Young, Jordyn oth Tjoa, Chris oth Kampman, Kyle oth Jones, David T. oth Mandell, David S. oth Enthalten in Elsevier Science Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment 2013 Amsterdam [u.a.] (DE-627)ELV011527242 volume:120 year:2021 pages:0 https://doi.org/10.1016/j.jsat.2020.108176 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_20 GBV_ILN_30 GBV_ILN_40 44.40 Pharmazie Pharmazeutika VZ AR 120 2021 0 |
| spelling |
10.1016/j.jsat.2020.108176 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001226.pica (DE-627)ELV052332691 (ELSEVIER)S0740-5472(20)30433-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.40 bkl Stewart, Rebecca E. verfasserin aut It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. Wolk, Courtney Benjamin oth Neimark, Geoffrey oth Vyas, Ridhi oth Young, Jordyn oth Tjoa, Chris oth Kampman, Kyle oth Jones, David T. oth Mandell, David S. oth Enthalten in Elsevier Science Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment 2013 Amsterdam [u.a.] (DE-627)ELV011527242 volume:120 year:2021 pages:0 https://doi.org/10.1016/j.jsat.2020.108176 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_20 GBV_ILN_30 GBV_ILN_40 44.40 Pharmazie Pharmazeutika VZ AR 120 2021 0 |
| allfields_unstemmed |
10.1016/j.jsat.2020.108176 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001226.pica (DE-627)ELV052332691 (ELSEVIER)S0740-5472(20)30433-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.40 bkl Stewart, Rebecca E. verfasserin aut It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. Wolk, Courtney Benjamin oth Neimark, Geoffrey oth Vyas, Ridhi oth Young, Jordyn oth Tjoa, Chris oth Kampman, Kyle oth Jones, David T. oth Mandell, David S. oth Enthalten in Elsevier Science Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment 2013 Amsterdam [u.a.] (DE-627)ELV011527242 volume:120 year:2021 pages:0 https://doi.org/10.1016/j.jsat.2020.108176 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_20 GBV_ILN_30 GBV_ILN_40 44.40 Pharmazie Pharmazeutika VZ AR 120 2021 0 |
| allfieldsGer |
10.1016/j.jsat.2020.108176 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001226.pica (DE-627)ELV052332691 (ELSEVIER)S0740-5472(20)30433-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.40 bkl Stewart, Rebecca E. verfasserin aut It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. Wolk, Courtney Benjamin oth Neimark, Geoffrey oth Vyas, Ridhi oth Young, Jordyn oth Tjoa, Chris oth Kampman, Kyle oth Jones, David T. oth Mandell, David S. oth Enthalten in Elsevier Science Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment 2013 Amsterdam [u.a.] (DE-627)ELV011527242 volume:120 year:2021 pages:0 https://doi.org/10.1016/j.jsat.2020.108176 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_20 GBV_ILN_30 GBV_ILN_40 44.40 Pharmazie Pharmazeutika VZ AR 120 2021 0 |
| allfieldsSound |
10.1016/j.jsat.2020.108176 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001226.pica (DE-627)ELV052332691 (ELSEVIER)S0740-5472(20)30433-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.40 bkl Stewart, Rebecca E. verfasserin aut It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. Wolk, Courtney Benjamin oth Neimark, Geoffrey oth Vyas, Ridhi oth Young, Jordyn oth Tjoa, Chris oth Kampman, Kyle oth Jones, David T. oth Mandell, David S. oth Enthalten in Elsevier Science Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment 2013 Amsterdam [u.a.] (DE-627)ELV011527242 volume:120 year:2021 pages:0 https://doi.org/10.1016/j.jsat.2020.108176 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_20 GBV_ILN_30 GBV_ILN_40 44.40 Pharmazie Pharmazeutika VZ AR 120 2021 0 |
| language |
English |
| source |
Enthalten in Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment Amsterdam [u.a.] volume:120 year:2021 pages:0 |
| sourceStr |
Enthalten in Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment Amsterdam [u.a.] volume:120 year:2021 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Pharmazie Pharmazeutika |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment |
| authorswithroles_txt_mv |
Stewart, Rebecca E. @@aut@@ Wolk, Courtney Benjamin @@oth@@ Neimark, Geoffrey @@oth@@ Vyas, Ridhi @@oth@@ Young, Jordyn @@oth@@ Tjoa, Chris @@oth@@ Kampman, Kyle @@oth@@ Jones, David T. @@oth@@ Mandell, David S. @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011527242 |
| dewey-sort |
3610 |
| id |
ELV052332691 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV052332691</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626033125.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jsat.2020.108176</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001226.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV052332691</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0740-5472(20)30433-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stewart, Rebecca E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wolk, Courtney Benjamin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Neimark, Geoffrey</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vyas, Ridhi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Young, Jordyn</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tjoa, Chris</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kampman, Kyle</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jones, David T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mandell, David S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011527242</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:120</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jsat.2020.108176</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_30</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="j">Pharmazie</subfield><subfield code="j">Pharmazeutika</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">120</subfield><subfield code="j">2021</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Stewart, Rebecca E. |
| spellingShingle |
Stewart, Rebecca E. ddc 610 bkl 44.40 It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment |
| authorStr |
Stewart, Rebecca E. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011527242 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.40 bkl It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment |
| topic |
ddc 610 bkl 44.40 |
| topic_unstemmed |
ddc 610 bkl 44.40 |
| topic_browse |
ddc 610 bkl 44.40 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
c b w cb cbw g n gn r v rv j y jy c t ct k k kk d t j dt dtj d s m ds dsm |
| hierarchy_parent_title |
Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment |
| hierarchy_parent_id |
ELV011527242 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011527242 |
| title |
It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment |
| ctrlnum |
(DE-627)ELV052332691 (ELSEVIER)S0740-5472(20)30433-5 |
| title_full |
It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment |
| author_sort |
Stewart, Rebecca E. |
| journal |
Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment |
| journalStr |
Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Stewart, Rebecca E. |
| container_volume |
120 |
| class |
610 VZ 44.40 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Stewart, Rebecca E. |
| doi_str_mv |
10.1016/j.jsat.2020.108176 |
| dewey-full |
610 |
| title_sort |
it's not just the money: the role of treatment ideology in publicly funded substance use disorder treatment |
| title_auth |
It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment |
| abstract |
Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. |
| abstractGer |
Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. |
| abstract_unstemmed |
Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_20 GBV_ILN_30 GBV_ILN_40 |
| title_short |
It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment |
| url |
https://doi.org/10.1016/j.jsat.2020.108176 |
| remote_bool |
true |
| author2 |
Wolk, Courtney Benjamin Neimark, Geoffrey Vyas, Ridhi Young, Jordyn Tjoa, Chris Kampman, Kyle Jones, David T. Mandell, David S. |
| author2Str |
Wolk, Courtney Benjamin Neimark, Geoffrey Vyas, Ridhi Young, Jordyn Tjoa, Chris Kampman, Kyle Jones, David T. Mandell, David S. |
| ppnlink |
ELV011527242 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.jsat.2020.108176 |
| up_date |
2024-07-06T22:43:38.259Z |
| _version_ |
1803871393688846336 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV052332691</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626033125.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jsat.2020.108176</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001226.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV052332691</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0740-5472(20)30433-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stewart, Rebecca E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wolk, Courtney Benjamin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Neimark, Geoffrey</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vyas, Ridhi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Young, Jordyn</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tjoa, Chris</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kampman, Kyle</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jones, David T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mandell, David S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011527242</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:120</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jsat.2020.108176</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_30</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="j">Pharmazie</subfield><subfield code="j">Pharmazeutika</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">120</subfield><subfield code="j">2021</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.3996916 |